Research Frontiers: Latest Peptide Science & Breakthroughs

This hub page indexes all Research Frontiers articles on ChemVerify. These deep-dive articles cover the latest breakthroughs in peptide science — from AI-driven drug discovery and GLP-1 receptor agonist research to clinical trial results and emerging therapeutic targets.

Each article is written for laboratory researchers and focuses on scientific evidence, mechanisms, and research implications. No medical advice is provided.

• AI-Driven Peptide Discovery: Machine Learning in Peptide Research → /learn/ai-peptide-discovery-2026 — AlphaFold impact, ML-driven sequence optimization, de novo design algorithms
• AI-Powered Peptide Discovery 2026: CreoPep, PepMimic and Machine Learning → /learn/ai-powered-peptide-discovery-2026 — ML platforms, affinity optimization, library screening, clinical pipeline statistics

• GLP-1 Agonists for Alzheimer's and Parkinson's: 2026 Research Update → /learn/glp-1-agonists-alzheimers-parkinsons-2026-research-update — LixiPark Phase II, EVOKE Phase III, neuroprotective mechanisms
• 23andMe Study: Genetic Variants Predict GLP-1 Drug Efficacy and Side Effects → /learn/23andme-genetic-variants-glp1-efficacy-side-effects — Pharmacogenomics in peptide therapeutics, GLP1R and GIPR variants
• Semaglutide and Chronic Kidney Disease: FLOW Trial Shows 24% Risk Reduction → /learn/semaglutide-chronic-kidney-disease-flow-trial-24-percent-risk-reduction — First GLP-1 RA kidney-protective outcomes trial
• Survodutide: Dual GLP-1/Glucagon Agonist Enters Phase 3 for MASH and Obesity → /learn/survodutide-dual-glp1-glucagon-agonist-phase-3-mash-obesity — Up to 18.7% body weight reduction, 83% MASH histologic improvement

• Longevity Peptides 2026: Epithalon, MOTS-C, Humanin and the Science of Aging → /learn/longevity-peptides-2026-epithalon-motsc-humanin — Telomerase, mitochondrial peptides, NAD+ pathways, senolytic research
• Epithalon and Telomere Research: What the Science Actually Shows → /learn/epithalon-telomere-research-science-evidence — Telomerase activation claims, Khavinson studies, evidence gaps
• Khavinson Bioregulator Peptides: A Complete Scientific Overview → /learn/khavinson-bioregulator-peptides-scientific-overview — Epithalon, Thymalin, Pinealon, epigenetic mechanisms
• Copper Peptides for Wound Healing Research: GHK-Cu Mechanism Deep Dive → /learn/copper-peptides-wound-healing-ghk-cu-mechanism — Copper ion delivery, MMP regulation, TGF-beta modulation

• Personalized Peptide Cancer Vaccines: Neoantigen Targeting in 31 Active Clinical Trials → /learn/personalized-peptide-cancer-vaccines-neoantigen-targeting-clinical-trials — 64.8% of personalized cancer vaccine trials are peptide-based
• Luna18: The Oral Peptide Achieving 47% Bioavailability → /learn/luna18-oral-peptide-47-percent-bioavailability — 11-mer cyclic peptide via mRNA display, no permeation enhancers needed
• CAQK: A Four-Amino-Acid Peptide That Could Stop Brain Damage After Injury → /learn/caqk-tetrapeptide-traumatic-brain-injury-neuroprotection — Selective homing to injured brain tissue, preclinical TBI results

• Antimicrobial Peptides: LL-37, Defensins, and the Post-Antibiotic Era → /learn/antimicrobial-peptides-ll37-defensins-post-antibiotic — AMPs as antibiotic alternatives, membrane disruption, biofilm activity
• Peptide Research for Hair Growth: GHK-Cu, PTD-DBM, and Copper Peptides → /learn/peptide-research-hair-growth-ghk-cu-copper — Dermal papilla cell models, follicle cycling studies

• BPC-157: Why Patients Trust a Peptide More Than a Statin — The Evidence Gap Explained → /learn/bpc-157-trust-paradox-evidence-gap — Inverse relationship between clinical evidence and public trust